Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TDS Pharm CoXKRX:464280 40 Pretax Margin % is 14.49% as of Jun. 2026, which is 4% below its 10-year median of 15.17. GuruFocus rates XKRX:464280 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review. Among 962 Drug Manufacturers companies, TDS Pharm Co ranks better than 78.59% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. TDS Pharm Co's Pre-Tax Income for the
three
months ended in Jun. 2026 was ₩1,170 Mil. TDS Pharm Co's Revenue for the
three
months ended in Jun. 2026 was ₩8,077 Mil. Therefore, TDS Pharm Co's pretax margin for the quarter that ended in Jun. 2026 was 14.49%.
The historical rank and industry rank for TDS Pharm Co's Pretax Margin % or its related term are showing as below:
XKRX:464280'
s Pretax Margin % Range Over the Past 10 Years
Min: 9.06 Med: 15.17 Max: 18.71
Current: 18.71
XKRX:464280's Pretax Margin % is ranked better than 78.59% of 962
companies
in the Drug Manufacturers industry
Industry Median: 7.155
vs XKRX:464280: 18.71
TDS Pharm Co (XKRX:464280) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
TDS Pharm Co Pretax Margin % Related Terms
TDS Pharm Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for TDS Pharm Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:464280 vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, TDS Pharm Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TDS Pharm Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TDS Pharm Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where TDS Pharm Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TDS Pharm Co (XKRX:464280) has a Pretax Margin % of 14.49% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TDS Pharm Co and its competitors. This is near median its historical median of 15.17. Over the past decade, TDS Pharm Co's Pretax Margin % has ranged from 9.06 to 18.71. According to the industry distribution chart, TDS Pharm Co ranks #206 out of 962 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is TDS Pharm Co's Pretax Margin % too high?
TDS Pharm Co's current Pretax Margin % of 14.49% is near median its 10-year median of 15.17. Over the past 10 years, this metric has ranged from a low of 9.06 to a high of 18.71. The Drug Manufacturers industry median Pretax Margin % is 7.16. TDS Pharm Co's value of 14.49% is 102.5% above this industry median. Based on the distribution chart, TDS Pharm Co ranks #206 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TDS Pharm Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does TDS Pharm Co's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, TDS Pharm Co ranks #206 out of 962 companies for Pretax Margin %. This places TDS Pharm Co in the top 21% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.16. TDS Pharm Co's value of 14.49% is 102.5% above this benchmark. Historically, TDS Pharm Co's own Pretax Margin % has ranged from 9.06 to 18.71 over the past decade. While the company's 10-year median is 15.17 vs. the industry median of 7.16, TDS Pharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TDS Pharm Co's current Pretax Margin % of 14.49% is 102.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TDS Pharm Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TDS Pharm Co's current Pretax Margin % is 14.49%, which is near median its own 10-year median of 15.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TDS Pharm Co stock overvalued right now?
TDS Pharm Co (XKRX:464280) has a current Pretax Margin % of 14.49%. The current Pretax Margin % is 14.49%, which is near median its 10-year median of 15.17 and 102.5% above the Drug Manufacturers industry median of 7.16. TDS Pharm Co's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For TDS Pharm Co (XKRX:464280), the current Pretax Margin % is 14.49% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
40GF Score
Get the complete analysis for XKRX:464280
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:464280 has been successfully added to your 
